Xiling Jiang

891 total citations
18 papers, 455 citations indexed

About

Xiling Jiang is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Xiling Jiang has authored 18 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Xiling Jiang's work include Monoclonal and Polyclonal Antibodies Research (6 papers), CAR-T cell therapy research (3 papers) and Acute Myeloid Leukemia Research (2 papers). Xiling Jiang is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), CAR-T cell therapy research (3 papers) and Acute Myeloid Leukemia Research (2 papers). Xiling Jiang collaborates with scholars based in United States, China and Netherlands. Xiling Jiang's co-authors include Lawrence J. Lesko, Stephan Schmidt, Weirong Wang, Marc R. Theoret, Richard Pazdur, Honghui Zhou, Steven J. Lemery, Lisa Rodríguez, Xi Chen and Jiang Liu and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Xiling Jiang

16 papers receiving 436 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiling Jiang United States 10 124 114 98 90 67 18 455
Abdel‐Baset Halim United States 10 117 0.9× 69 0.6× 201 2.1× 22 0.2× 66 1.0× 19 557
Lizhu Han China 9 145 1.2× 22 0.2× 73 0.7× 61 0.7× 47 0.7× 27 358
Ruth Roberts United Kingdom 4 150 1.2× 115 1.0× 219 2.2× 49 0.5× 16 0.2× 8 498
Linda P. Briley United States 10 120 1.0× 27 0.2× 255 2.6× 39 0.4× 46 0.7× 21 672
Søren Astrup Jensen Denmark 13 393 3.2× 243 2.1× 93 0.9× 15 0.2× 45 0.7× 21 654
Brad Hirakawa United States 10 133 1.1× 96 0.8× 318 3.2× 25 0.3× 25 0.4× 18 566
I. A. G. Reilly United Kingdom 12 93 0.8× 141 1.2× 105 1.1× 94 1.0× 14 0.2× 16 584
Xiaoming Zha China 17 290 2.3× 37 0.3× 251 2.6× 49 0.5× 86 1.3× 58 902

Countries citing papers authored by Xiling Jiang

Since Specialization
Citations

This map shows the geographic impact of Xiling Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiling Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiling Jiang more than expected).

Fields of papers citing papers by Xiling Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiling Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiling Jiang. The network helps show where Xiling Jiang may publish in the future.

Co-authorship network of co-authors of Xiling Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiling Jiang. A scholar is included among the top collaborators of Xiling Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiling Jiang. Xiling Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Rabik, Cara A., Shu Wang, Donna Przepiorka, et al.. (2025). FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy. Clinical Cancer Research. 31(20). 4230–4238.
2.
Woods, Ashley, Kelly J. Norsworthy, Moran Choe, et al.. (2024). FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation. Clinical Cancer Research. 31(1). 12–17. 1 indexed citations
3.
4.
Jiang, Xiling, et al.. (2024). Gut microbiota and oral cavity cancer: a two-sample bidirectional Mendelian randomization study. Frontiers in Oncology. 14. 1389678–1389678. 1 indexed citations
5.
Woods, Ashley, Kelly J. Norsworthy, Jonathon Vallejo, et al.. (2023). FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. Clinical Cancer Research. 30(7). 1226–1231. 16 indexed citations
6.
Bai, Jane P. F., et al.. (2023). Quantitative Systems Pharmacology for Rare Disease Drug Development. Journal of Pharmaceutical Sciences. 112(9). 2313–2320. 11 indexed citations
7.
Jiang, Xiling, Zeyu Zhao, Hans Jacquemyn, et al.. (2022). Addition of fungal inoculum increases seed germination and protocorm formation in a terrestrial orchid. Global Ecology and Conservation. 38. e02235–e02235. 9 indexed citations
8.
Ge, Lingling, et al.. (2021). [Comparison of apical root resorption of maxillary incisors between adolescents and adults after orthodontic treatment].. PubMed. 30(2). 187–190. 1 indexed citations
9.
10.
11.
Casak, Sandra J., Martha Donoghue, Lola A. Fashoyin‐Aje, et al.. (2020). FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma. Clinical Cancer Research. 27(7). 1836–1841. 130 indexed citations
12.
Jiang, Xiling, et al.. (2018). Development and Translational Application of a Minimal Physiologically Based Pharmacokinetic Model for a Monoclonal Antibody against Interleukin 23 (IL-23) in IL-23-Induced Psoriasis-Like Mice. Journal of Pharmacology and Experimental Therapeutics. 365(1). 140–155. 18 indexed citations
13.
14.
Chen, Xi, Xiling Jiang, William J. Jusko, Honghui Zhou, & Weirong Wang. (2016). Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis. Journal of Pharmacokinetics and Pharmacodynamics. 43(3). 291–304. 30 indexed citations
15.
Jiang, Xiling, Jocelyn H. Leu, Indrajeet Singh, Linda A. Snyder, & Weirong Wang. (2016). Abstract 2085: Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize tumor killing effect of an anti-VISTA monoclonal antibody in tumor bearing mice. Cancer Research. 76(14_Supplement). 2085–2085. 1 indexed citations
16.
Jiang, Xiling, Joshua P. Lewis, Richard B. Horenstein, et al.. (2015). Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults. European Journal of Pharmaceutical Sciences. 82. 64–78. 24 indexed citations
17.
Jiang, Xiling, et al.. (2015). Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. Clinical Pharmacokinetics. 54(2). 147–166. 141 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abdel‐Baset Halim Breakdown of academic impact, for papers by Lizhu Han Breakdown of academic impact, for papers by Ruth Roberts Breakdown of academic impact, for papers by Linda P. Briley Breakdown of academic impact, for papers by Søren Astrup Jensen Breakdown of academic impact, for papers by Brad Hirakawa Breakdown of academic impact, for papers by I. A. G. Reilly Breakdown of academic impact, for papers by Xiaoming Zha
Rankless by CCL
2026